PCI Biotech Holding ASA (LTS:0JGL) Total Inventories: kr0.00 Mil (As of Jun. 2025)


What is PCI Biotech Holding ASA Total Inventories?

PCI Biotech Holding ASA LTS:0JGL Total Inventories is kr0.00 Mil as of Jun. 2025. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's total inventories for the quarter that ended in Jun. 2025 was kr0.00 Mil. PCI Biotech Holding ASA's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Jun. 2025 was kr0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. PCI Biotech Holding ASA's Net-Net Working Capital per share for the quarter that ended in Jun. 2025 was kr0.29.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PCI Biotech Holding ASA  (LTS:0JGL) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

PCI Biotech Holding ASA's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2025 is

Net-Net Working Capital Per Share (Q: Jun. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(13.617+0.75 * 4.052+0.5 * 0-6.008
-0-0)/37.326
=0.29

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

PCI Biotech Holding ASA's Days Inventory for the six months ended in Jun. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2025 )/Cost of Goods Sold (Q: Jun. 2025 )*Days in Period
=0/0*365 / 2
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

PCI Biotech Holding ASA's Inventory Turnover for the quarter that ended in Jun. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2025 ) / Average Total Inventories (Q: Jun. 2025 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

PCI Biotech Holding ASA's Inventory to Revenue for the quarter that ended in Jun. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2025 ) / Revenue (Q: Jun. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

PCI Biotech Holding ASA Total Inventories Related Terms

PCI Biotech Holding ASA Total Inventories Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Total Inventories Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of kr0.00 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Total Inventories of kr0.00 Mil as of Jun. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Total Inventories too high?
PCI Biotech Holding ASA's current Total Inventories is kr0.00 Mil.
How does PCI Biotech Holding ASA's Total Inventories compare to VRTX and REGN?
PCI Biotech Holding ASA's Total Inventories of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Total Inventories is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Total Inventories of kr0.00 Mil. The current Total Inventories is kr0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Total Inventories is kr0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.